Douglas R Stewart1, Ana F Best1, Gretchen M Williams2,3, Laura A Harney4, Ann G Carr4, Anne K Harris2,3,5, Christian P Kratz6, Louis P Dehner3,5,7, Yoav H Messinger2,3, Philip S Rosenberg1, D Ashley Hill8,9, Kris Ann P Schultz2,3,5. 1. 1 National Cancer Institute, Rockville, MD. 2. 2 Children's Hospitals and Clinics of Minnesota, Minneapolis, MN. 3. 3 International Pleuropulmonary Blastoma/ DICER1 Registry, Minneapolis, MN. 4. 4 Westat, Rockville, MD. 5. 5 International Ovarian and Testicular Stromal Tumor Registry, Minneapolis, MN. 6. 6 Hannover Medical School, Hannover, Germany. 7. 7 Washington University, St. Louis, MO. 8. 8 Children's National Health System, Washington, DC. 9. 9 George Washington University School of Medicine and Health Sciences, Washington, DC.
Abstract
PURPOSE: DICER1 syndrome is an autosomal-dominant, pleiotropic tumor-predisposition disorder caused by pathogenic germline variants in DICER1. We sought to quantify risk, hazard rates, and the probability of neoplasm incidence accounting for competing risks ("cumulative incidence") of neoplasms (benign and malignant) and standardized incidence ratios for malignant tumors in individuals with DICER1 pathogenic variation. PATIENTS AND METHODS: We combined data from three large cohorts of patients who carry germline pathogenic variation in DICER1. To reduce ascertainment bias, we distinguished probands from nonprobands. Neoplasm diagnoses were confirmed by review of pathology reports and/or central review of surgical pathology materials. Standardized cancer incidence ratios were determined relative to the SEER program, which does not capture all DICER1-associated neoplasms. For all malignancies and benign tumors ("neoplasms," excluding type Ir pleuropulmonary blastoma and thyroid nodules), we used the Kaplan-Meier method and nonparametric cumulative incidence curves to estimate neoplasm-free survival. RESULTS: We calculated the age at first neoplasm diagnosis (systematically ascertained cancers plus DICER1-associated neoplasms pleuropulmonary blastoma, cystic nephroma, and nasal chondromesenchymal hamartoma) in 102 female and male nonproband DICER1 carriers. By age 10 years, 5.3% (95% CI, 0.6% to 9.7%) of nonproband DICER1 carriers had developed a neoplasm (females, 4.0%; males, 6.6%). By age 50 years, 19.3% (95% CI, 8.4% to 29.0%) of nonprobands had developed a neoplasm (females, 26.5%; males, 10.2%). After age 10 years, female risk was elevated compared with male risk. Standardized cancer incidence ratio analysis of 102 nonproband DICER1 carriers, which represented 3,344 person-years of observation, showed significant cancer excesses overall, particularly of gynecologic and thyroid cancers. CONCLUSION: This work provides the first quantitative analysis of site-specific neoplasm risk and excess malignancy risk in 102 systematically characterized nonproband DICER1 carriers. Our findings inform DICER1 syndrome phenotype, natural history, and genetic counseling.
PURPOSE:DICER1 syndrome is an autosomal-dominant, pleiotropic tumor-predisposition disorder caused by pathogenic germline variants in DICER1. We sought to quantify risk, hazard rates, and the probability of neoplasm incidence accounting for competing risks ("cumulative incidence") of neoplasms (benign and malignant) and standardized incidence ratios for malignant tumors in individuals with DICER1 pathogenic variation. PATIENTS AND METHODS: We combined data from three large cohorts of patients who carry germline pathogenic variation in DICER1. To reduce ascertainment bias, we distinguished probands from nonprobands. Neoplasm diagnoses were confirmed by review of pathology reports and/or central review of surgical pathology materials. Standardized cancer incidence ratios were determined relative to the SEER program, which does not capture all DICER1-associated neoplasms. For all malignancies and benign tumors ("neoplasms," excluding type Ir pleuropulmonary blastoma and thyroid nodules), we used the Kaplan-Meier method and nonparametric cumulative incidence curves to estimate neoplasm-free survival. RESULTS: We calculated the age at first neoplasm diagnosis (systematically ascertained cancers plus DICER1-associated neoplasms pleuropulmonary blastoma, cystic nephroma, and nasal chondromesenchymal hamartoma) in 102 female and male nonproband DICER1 carriers. By age 10 years, 5.3% (95% CI, 0.6% to 9.7%) of nonproband DICER1 carriers had developed a neoplasm (females, 4.0%; males, 6.6%). By age 50 years, 19.3% (95% CI, 8.4% to 29.0%) of nonprobands had developed a neoplasm (females, 26.5%; males, 10.2%). After age 10 years, female risk was elevated compared with male risk. Standardized cancer incidence ratio analysis of 102 nonproband DICER1 carriers, which represented 3,344 person-years of observation, showed significant cancer excesses overall, particularly of gynecologic and thyroid cancers. CONCLUSION: This work provides the first quantitative analysis of site-specific neoplasm risk and excess malignancy risk in 102 systematically characterized nonproband DICER1 carriers. Our findings inform DICER1 syndrome phenotype, natural history, and genetic counseling.
Authors: M S Anglesio; Y Wang; W Yang; J Senz; A Wan; A Heravi-Moussavi; C Salamanca; S Maines-Bandiera; D G Huntsman; G B Morin Journal: J Pathol Date: 2013-02 Impact factor: 7.996
Authors: Mark Brenneman; Amanda Field; Jiandong Yang; Gretchen Williams; Leslie Doros; Christopher Rossi; Kris Ann Schultz; Avi Rosenberg; Jennifer Ivanovich; Joyce Turner; Heather Gordish-Dressman; Douglas Stewart; Weiying Yu; Anne Harris; Peter Schoettler; Paul Goodfellow; Louis Dehner; Yoav Messinger; D Ashley Hill Journal: F1000Res Date: 2015-07-10
Authors: Kris Ann P Schultz; Surya P Rednam; Junne Kamihara; Leslie Doros; Maria Isabel Achatz; Jonathan D Wasserman; Lisa R Diller; Laurence Brugières; Harriet Druker; Katherine A Schneider; Rose B McGee; William D Foulkes Journal: Clin Cancer Res Date: 2017-06-15 Impact factor: 12.531
Authors: Douglas R Stewart; Yoav Messinger; Gretchen M Williams; Jiandong Yang; Amanda Field; Kris Ann P Schultz; Laura A Harney; Leslie A Doros; Louis P Dehner; D Ashley Hill Journal: Hum Genet Date: 2014-08-14 Impact factor: 4.132
Authors: J R Priest; J Watterson; L Strong; V Huff; W G Woods; R L Byrd; S H Friend; I Newsham; M D Amylon; A Pappo; D H Mahoney; C Langston; R Heyn; G Kohut; D R Freyer; B Bostrom; M S Richardson; J Barredo; L P Dehner Journal: J Pediatr Date: 1996-02 Impact factor: 4.406
Authors: D Ashley Hill; Jennifer Ivanovich; John R Priest; Christina A Gurnett; Louis P Dehner; David Desruisseau; Jason A Jarzembowski; Kathryn A Wikenheiser-Brokamp; Brian K Suarez; Alison J Whelan; Gretchen Williams; Dawn Bracamontes; Yoav Messinger; Paul J Goodfellow Journal: Science Date: 2009-06-25 Impact factor: 47.728
Authors: T J Pugh; W Yu; J Yang; A L Field; L Ambrogio; S L Carter; K Cibulskis; P Giannikopoulos; A Kiezun; J Kim; A McKenna; E Nickerson; G Getz; S Hoffher; Y H Messinger; L P Dehner; C W M Roberts; C Rodriguez-Galindo; G M Williams; C T Rossi; M Meyerson; D A Hill Journal: Oncogene Date: 2014-06-09 Impact factor: 9.867
Authors: Karoline B Kuchenbaecker; John L Hopper; Daniel R Barnes; Kelly-Anne Phillips; Thea M Mooij; Marie-José Roos-Blom; Sarah Jervis; Flora E van Leeuwen; Roger L Milne; Nadine Andrieu; David E Goldgar; Mary Beth Terry; Matti A Rookus; Douglas F Easton; Antonis C Antoniou; Lesley McGuffog; D Gareth Evans; Daniel Barrowdale; Debra Frost; Julian Adlard; Kai-Ren Ong; Louise Izatt; Marc Tischkowitz; Ros Eeles; Rosemarie Davidson; Shirley Hodgson; Steve Ellis; Catherine Nogues; Christine Lasset; Dominique Stoppa-Lyonnet; Jean-Pierre Fricker; Laurence Faivre; Pascaline Berthet; Maartje J Hooning; Lizet E van der Kolk; Carolien M Kets; Muriel A Adank; Esther M John; Wendy K Chung; Irene L Andrulis; Melissa Southey; Mary B Daly; Saundra S Buys; Ana Osorio; Christoph Engel; Karin Kast; Rita K Schmutzler; Trinidad Caldes; Anna Jakubowska; Jacques Simard; Michael L Friedlander; Sue-Anne McLachlan; Eva Machackova; Lenka Foretova; Yen Y Tan; Christian F Singer; Edith Olah; Anne-Marie Gerdes; Brita Arver; Håkan Olsson Journal: JAMA Date: 2017-06-20 Impact factor: 56.272
Authors: Lauren M Vasta; Mary L McMaster; Laura A Harney; Alexander Ling; Jung Kim; Anne K Harris; Ann G Carr; Scott M Damrauer; Daniel J Rader; Rachel L Kember; Peter A Kanetsky; Katherine L Nathanson; Louise C Pyle; Mark H Greene; Kris Ann Schultz; Douglas R Stewart Journal: Cancer Genet Date: 2020-10-24
Authors: Melissa A Merideth; Laura A Harney; Nina Vyas; Averyl Bachi; Ann Garrity Carr; D Ashley Hill; Louis P Dehner; Kris Ann P Schultz; Douglas R Stewart; Pamela Stratton Journal: Gynecol Oncol Date: 2020-01-15 Impact factor: 5.482
Authors: Anthony P Y Liu; Megan M Kelsey; Nelly Sabbaghian; Sung-Hye Park; Cheri L Deal; Adam J Esbenshade; Oswald Ploner; Andrew Peet; Heidi Traunecker; Yomna H E Ahmed; Margaret Zacharin; Anatoly Tiulpakov; Anastasia M Lapshina; Andrew W Walter; Pinaki Dutta; Ashutosh Rai; Márta Korbonits; Leanne de Kock; Kim E Nichols; William D Foulkes; John R Priest Journal: J Clin Endocrinol Metab Date: 2021-01-23 Impact factor: 5.958
Authors: Lauren M Vasta; Alison Nichols; Laura A Harney; Ana F Best; Ann G Carr; Anne K Harris; Markku Miettinen; Kris Ann P Schultz; Hung Jeffrey Kim; Douglas R Stewart Journal: Rhinol Online Date: 2020-04-13